Zhejiang Taimei Medical Technology Co., Ltd. (Taimei Tech) disclosed a share buyback executed on 6 October 2026, purchasing 15,200 H-shares on the Hong Kong Stock Exchange.

The shares were repurchased within a price range of HKD 4.745 to HKD 4.890, at a volume-weighted average cost of HKD 4.8182 per share. The transaction totalled HKD 0.07 million, increasing Taimei Tech’s treasury stock from 7.38 million to 7.40 million shares.

Following the buyback, the company’s outstanding share count (excluding treasury shares) decreased marginally by 0.01 % to 193.19 million. Total issued shares remain unchanged at 200.59 million, as the repurchased shares are held in treasury and have not been cancelled.

The repurchase forms part of a mandate approved on 23 June 2026 that authorises Taimei Tech to buy back up to 20.02 million shares. Cumulative repurchases under this mandate now stand at 6.98 million shares, representing 3.49 % of the company’s outstanding shares as of the mandate date.

In line with Hong Kong listing regulations, Taimei Tech is subject to a 30-day moratorium on issuing new shares or transferring treasury shares, effective until 5 November 2026.